comparemela.com

Respiratory Tract Cancer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gilead s stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappoints

Shares of Gilead Sciences tumbled 9.7% early Monday after the company reported disappointing lung-cancer trial results.

Merdad parseyGilead sciences incGilead sciencesChief medical officer merdadArticle normalHealthcare life sciencesRegulation government policyFinancial performanceAnalysts amp 39 comments recommendationsShare price movement disruptionsOwnership changesAcquisitions mergers shareholdingsCorporate actionsCorporate industrial newsPolitical general newsRespiratory tract diseases

Sanofi Ends Drug Program After Late-Stage Trial in Lung Cancer Fails

By Adria Calatayud Sanofi said it would end a clinical-development program for its tusamitamab ravtansine drug candidate after a late-stage trial in.

Adria calatayudArticle normalHealthcare life sciencesNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingPolitical general newsRespiratory tract diseasesRespiratory tract cancerMedical conditionsContent typesFactiva filtersC amp ampe industry news filterSan fr

Sanofi suffers major blow as its cutting-edge cancer drug disappoints in Phase III trials

French pharmaceuticals giant Sanofi on Thursday said it would be halting development of a promising cancer treatment after the cutting-edge candidate failed.

France generalUnited statesTusamitamab ravtansinDietmar bergerTusamitamab ravtansineArticle normalCancer drugsHealthcare life sciencesSpecialized drugs medicationsNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingPolitical general newsChemotherapy radiotherapy immunotherapy

BioAffinity Shares Rise on Addition to Government Pay Schedule

By Dean Seal Shares of BioAffinity Technologies jumped after the Centers for Medicare and Medicaid Services made a final determination to pay for the.

San antonioUnited statesMaria zannesCenters for medicareMedicaid servicesBioaffinity technologiesCypath lungExecutive maria zannesDean sealArticle normalMedical equipment suppliesHealthcare life sciencesMedical devices apparatusDiagnostic therapeutic devicesFinancial performanceShare price movement disruptions

AbbVie s Experimental Therapy Shows Reduction in Type of Lung Cancer in Phase 2 Study

By Colin Kellaher AbbVie said Wednesday that a Phase 2 study of its experimental drug telisotuzumab-vedotin, or teliso-V, showed a reduction in disease in.

Colin kellaherArticle normalBiotechnology servicesCancer drugsHealthcare life sciencesSpecialized drugs medicationsNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingPolitical general newsRespiratory tract diseasesRespiratory tract cancerMedical conditionsContent types

vimarsana © 2020. All Rights Reserved.